Sasako Mitsuru, Sano Takeshi, Yamamoto Seiichiro, Sairenji Motonori, Arai Kuniyoshi, Kinoshita Taira, Nashimoto Atsushi, Hiratsuka Masahiro
National Cancer Centre, Tokyo, Japan.
Lancet Oncol. 2006 Aug;7(8):644-51. doi: 10.1016/S1470-2045(06)70766-5.
Because of the inaccessibility of mediastinal nodal metastases, the left thoracoabdominal approach (LTA) has often been used to treat gastric cancer of the cardia or subcardia. In a randomised phase III study, we aimed to compare LTA with the abdominal-transhiatal approach (TH) in the treatment of these tumours.
Between July, 1995, and December, 2003, 167 patients were enrolled from 27 Japanese hospitals and randomly assigned to TH (n=82) or LTA (n=85). The primary endpoint was overall survival, and secondary endpoints were disease-free survival, postoperative morbidity and hospital mortality, and postoperative symptoms and change of respiratory function. The projected sample size was 302. After the first interim analysis, the predicted probability of LTA having a significantly better overall survival than TH at the final analysis was only 3.65%, and the trial was closed immediately. Analysis was by intention to treat. This study is registered with , number NCT00149266.
5-year overall survival was 52.3% (95% CI 40.4-64.1) in the TH group and 37.9% (26.1-49.6) in the LTA group. The hazard ratio of death for LTA compared with TH was 1.36 (0.89-2.08, p=0.92). Three patients died in hospital after LTA but none after TH. Morbidity was worse after LTA than after TH.
Because LTA does not improve survival after TH and leads to increased morbidity in patients with cancer of the cardia or subcardia, LTA cannot be justified to treat these tumours.
由于纵隔淋巴结转移难以触及,左胸腹联合入路(LTA)常被用于治疗贲门或贲门下胃癌。在一项随机III期研究中,我们旨在比较LTA与经腹食管裂孔入路(TH)治疗这些肿瘤的效果。
1995年7月至2003年12月期间,从27家日本医院招募了167例患者,并随机分配至TH组(n = 82)或LTA组(n = 85)。主要终点为总生存期,次要终点为无病生存期、术后发病率和医院死亡率,以及术后症状和呼吸功能变化。预计样本量为302例。首次中期分析后,最终分析时LTA的总生存期显著优于TH的预测概率仅为3.65%,试验立即终止。分析采用意向性治疗。本研究已在 注册,编号为NCT00149266。
TH组5年总生存率为52.3%(95%CI 40.4 - 64.1),LTA组为37.9%(26.1 - 49.6)。LTA与TH相比的死亡风险比为1.36(0.89 - 2.08,p = 0.92)。LTA术后有3例患者在医院死亡,而TH术后无死亡病例。LTA术后的发病率高于TH术后。
由于LTA不能提高TH术后的生存率,且会导致贲门或贲门下癌患者的发病率增加,因此LTA不能作为治疗这些肿瘤的合理方法。